NCT06755814 ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)
| NCT ID | NCT06755814 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Societa Italiana di Pneumologia |
| Condition | Community Acquired Pneumonia (CAP) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,298 participants |
| Start Date | 2025-08-11 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,298 participants in total. It began in 2025-08-11 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicentric, prospective study aims at: evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical, microbiological and genetic analysis on collected samples.
Eligibility Criteria
Inclusion Criteria: Hospitalized patients with a confirmed diagnosis of Community-Acquired Pneumonia (CAP) characterized by at least one of the following risk factors for immunosuppression: * AIDS, * Aplastic anemia; * Asplenia; * Hematologic malignancy (e.g., lymphoma/acute or chronic myeloid leukemia/multiple myeloma); * Chemotherapy within the last 3 months; * Neutropenia defined as a white blood cell count less than 500/dL on a complete blood count; * Use of biologics (including trastuzumab and therapy for autoimmune diseases (e.g., anti-TNF α), prescribed within the last 6 months before hospital admission; * Solid organ transplant; * Bone marrow transplant; * Chronic oral steroid use (\>10 mg/day prednisone or equivalent ≥3 months before accessing the ED, or cumulative dose \> 600 mg prednisone); * Use of corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent ≥14 days or cumulative dose \> 600 mg prednisone; * Active malignancy; * Malignancy within one year of pneumonia (excluding patients with localized skin cancer or early-stage malignancy); * Lung malignancy with neutropenia/chemotherapy; * Other solid malignancy with neutropenia/chemotherapy; * Other immunodeficiency (including congenital/genetic immunosuppression and immunosuppressive therapy secondary to hematologic malignancy or solid malignancy); * Primary immunodeficiency. Exclusion Criteria: * None
Contact & Investigator
Francesco B.A. Blasi, MD
STUDY CHAIR
Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Frequently Asked Questions
Who can join the NCT06755814 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Community Acquired Pneumonia (CAP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06755814 currently recruiting?
Yes, NCT06755814 is actively recruiting participants. Contact the research team at francesco.blasi@unimi.it for enrollment information.
Where is the NCT06755814 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06755814 clinical trial?
NCT06755814 is sponsored by Societa Italiana di Pneumologia. The principal investigator is Francesco B.A. Blasi, MD at Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico. The trial plans to enroll 1,298 participants.